CompletedNot Applicable

Calprotectin and Ischemia Modified Albumin Serum to Measure Disease Activity in Behçet's Disease

Egypt60 participantsStarted 2019-04-01

Plain-language summary

Behçet's Disease activity was evaluated using BD Current Activity Form (BDCAF). Serum calprotectin and IMA concentrations were compared among active BD cases, inactive BD cases and control subjects.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * new case of Behçet's disease available medical record Well known duration of BD, Well known current treatment used Well known current organ involvement Exclusion Criteria: * concomitant autoimmune or auto-inflammatory disorder; acute or chronic infections; cancer; diabetes; heart failure; gestation or up to six months after birth

What they're measuring

BD activity was evaluated using BD Current Activity Form (BDCAF).

Timeframe: 3 years

Serum calprotectin concentrations

Timeframe: 3 years

Ischaemia Modified Albumin (IMA) serum concentrations

Timeframe: 3 years

Trial details

NCT IDNCT05868538

SponsorMansoura University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-03-01

View on ClinicalTrials.gov More Behçet's Diseasecases trials